The relationship between chronic kidney disease and erectile dysfunction is one of the most consistent and underdiscussed associations in men's health. While erectile dysfunction (ED) is common in the general male population, its prevalence rises dramatically as kidney function declines—reaching rates that dwarf those seen in men without renal impairment. For a man with reduced kidney function, difficulty achieving or maintaining an erection is not an isolated inconvenience but a visible marker of the same vascular, hormonal, and metabolic disturbances that drive kidney disease itself. Understanding why the two conditions travel together helps clarify both the biology of erections and the systemic nature of chronic kidney disease.
How Common Is Erectile Dysfunction in Chronic Kidney Disease?
The numbers are striking. A systematic review and meta-analysis of men with chronic kidney disease reported an overall ED prevalence of roughly 76%, far above the 20–40% typically cited for middle-aged men in the general population [1]. When stratified by disease stage, prevalence remained high across the spectrum: approximately 78% in men with pre-dialysis CKD, 77% in those on hemodialysis, and 64% among kidney transplant recipients [1].
Transplantation appears to attenuate but not eliminate the problem. A 2025 systematic review and meta-analysis focused specifically on kidney transplant recipients found a pooled ED prevalence of about 53%, with diabetes mellitus emerging as a significant associated factor [2]. Earlier meta-analytic work on self-reported sexual dysfunction in CKD populations similarly documented that erectile difficulties, reduced libido, and diminished sexual satisfaction are common and frequently coexist [3]. Taken together, the data suggest that the majority of men with meaningful kidney impairment experience some degree of erectile dysfunction, and that the burden scales with disease severity.
Why the Kidneys and Erections Are Connected
An erection is fundamentally a vascular event. Sexual arousal triggers the release of nitric oxide in the penile blood vessels, which relaxes smooth muscle, allows the arteries to dilate, and increases blood flow into the erectile tissue. Anything that impairs the health of the vascular endothelium—the thin cellular lining of blood vessels—undermines this process. Chronic kidney disease is, in many respects, a disease of the endothelium.
As kidney function declines, several interlocking mechanisms converge to impair erectile function [4]:
- Endothelial dysfunction: Uremic toxins, oxidative stress, and chronic inflammation reduce nitric oxide bioavailability, blunting the vasodilation that erections require.
- Accelerated vascular disease: CKD promotes arterial stiffness and atherosclerosis, narrowing and hardening the small arteries that supply the penis—vessels that are among the first to show functional decline.
- Hormonal disruption: Reduced kidney function is associated with hypogonadism and lower testosterone, along with elevated prolactin, disturbing the hormonal signaling that supports libido and erectile capacity.
- Autonomic and peripheral neuropathy: Uremia and coexisting diabetes damage the nerves that initiate and coordinate the erectile response.
- Psychological burden: Depression, anxiety, and the physical toll of dialysis or transplantation contribute an important psychogenic component.
Because these mechanisms overlap so heavily with the pathophysiology of cardiovascular disease, ED in a man with CKD is best understood not as a separate condition but as one manifestation of widespread vascular and endocrine dysfunction.
Vitamin D, Mineral Metabolism, and Vascular Health
One thread connecting kidney disease to erectile function runs through mineral and vitamin D metabolism. The kidneys are responsible for the final activation of vitamin D, and as function declines, deficiency of active vitamin D becomes nearly universal in advanced CKD. Vitamin D deficiency has itself been independently associated with erectile dysfunction in observational research, plausibly through effects on endothelial function and nitric oxide signaling.
CKD also disturbs calcium, phosphate, and vascular calcification pathways, further accelerating the arterial stiffening that impairs penile blood flow. While correcting a deficiency is not a treatment for established ED, maintaining adequate vitamin D status is part of the broader vascular-protective picture, and clinical studies suggest that men with better vascular health tend to experience better erectile function. This is one reason clinicians increasingly consider the full metabolic profile—not just the erectile symptom in isolation—when evaluating men with kidney disease.
Erectile Dysfunction as a Marker of Disease Severity
Beyond its impact on quality of life, erectile dysfunction carries prognostic weight. In the general population, ED is a well-established early warning sign of cardiovascular disease, often preceding a heart attack or stroke by several years because the small penile arteries reveal endothelial damage before larger vessels do. In men with chronic kidney disease—who already carry a substantially elevated cardiovascular risk—the presence and severity of ED may reflect the overall burden of vascular disease [4].
This reframes the symptom as clinically meaningful information rather than a purely quality-of-life concern. A man who reports new or worsening erectile difficulties alongside declining kidney function is, in effect, reporting on the state of his vascular system. That makes ED a useful, if uncomfortable, prompt for comprehensive cardiovascular and metabolic assessment. It also underscores why erectile symptoms in this population deserve medical evaluation rather than self-management.
Treatment Considerations in Kidney Disease
The good news is that erectile dysfunction in men with chronic kidney disease is often treatable, and the evidence base supporting phosphodiesterase type 5 (PDE5) inhibitors—the drug class that includes tadalafil, sildenafil, and vardenafil—is reassuring. A pooled analysis of PDE5 inhibitor treatment in patients with end-stage renal disease receiving dialysis or after renal transplantation found these agents to be efficacious and generally well tolerated in this population [5]. PDE5 inhibitors work by amplifying the same nitric oxide pathway that CKD impairs, helping to restore the vasodilation needed for an erection.
Several caveats matter, however, and they are the reason treatment in this group should always be physician-supervised. Kidney impairment alters drug clearance, so dosing frequently needs adjustment, and starting doses are often conservative. Many men with CKD take antihypertensives and, critically, some take nitrates—a combination with PDE5 inhibitors that can cause dangerous drops in blood pressure. Coexisting conditions such as diabetes and cardiovascular disease further individualize the risk-benefit calculation. Daily low-dose regimens, such as once-daily tadalafil, are one option that some clinicians favor for tolerability and steady-state dosing, though the right approach depends entirely on the individual's kidney function, medications, and comorbidities [5]. Interestingly, preclinical research has even suggested PDE5 inhibitors may exert renoprotective effects in models of chronic kidney disease, though this remains investigational and is not an established clinical indication [6].
The overarching principle is that treatment must be integrated with the management of the underlying kidney disease and its cardiovascular context—not layered on top of it in isolation.
Conclusion
Chronic kidney disease and erectile dysfunction are bound together by shared biology: impaired endothelial function, accelerated vascular disease, hormonal disruption, and neuropathy all conspire to make ED one of the most common—and most telling—complications of declining kidney function. With prevalence estimates reaching 70–80% in advanced disease, erectile difficulty in this population is the rule rather than the exception. Yet it is also frequently treatable, and its presence offers valuable insight into a man's overall vascular health. The evidence-based message is that ED in kidney disease should be taken seriously, evaluated in its full metabolic and cardiovascular context, and managed by a clinician who can weigh kidney function, concurrent medications, and comorbidities together.
For men navigating erectile difficulties in the context of broader health concerns, clinical formulation and medical oversight matter. If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com—including daily formulations like EPIQ Chews, which pair low-dose tadalafil and vardenafil with vitamin D3 and K2. You can read more men's vascular health research on the OnyxMD blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Pizzol D, Xiao T, Smith L, et al. Prevalence of erectile dysfunction in patients with chronic kidney disease: a systematic review and meta-analysis. International Journal of Impotence Research. 2021;33(5):508-515. doi:10.1038/s41443-020-0295-8
Prevalence and risk factors of erectile dysfunction in kidney transplant recipients: a systematic review and meta-analysis. Medicine (Baltimore). 2025;104(30):e43. doi:10.1097/MD.0000000000043
Navaneethan SD, Vecchio M, Johnson DW, et al. Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. American Journal of Kidney Diseases. 2010;56(4):670-685. doi:10.1053/j.ajkd.2010.06.016
Erectile dysfunction in chronic kidney disease and hemodialysis patients: a state-of-the-art review. Cureus. 2025;17(3):e11927523. doi:10.7759/cureus.11927523
Lasaponara F, Sedigh O, Pasquale G, et al. Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation. The Journal of Sexual Medicine. 2013;10(11):2798-2814. doi:10.1111/jsm.12038
Ahmed LA, Mohamed AF, Abd El-Haleim EA, El-Tanbouly DM. The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease. Fundamental & Clinical Pharmacology. 2020;34(5):568-578. doi:10.1111/fcp.12564
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.